Chinese medicine, Fuzhenghuayu (FZHY), appears to prevent fibrosis progression and improve liver function in humans. Here we found that FZHY enhanced hepatocyte differentiation from human embryonic stem cells (hESC). After treatment with FZHY, albumin expression was consistently increased during differentiation and maturation process, and expression of metabolizing enzymes and transporter were also increased. Importantly, expression of mesenchymal cell and cholangiocyte marker was significantly reduced by treatment with FZHY, indicating that one possible mechanism of FZHY's role is to inhibit the formation of mesenchymal cells and cholangiocytes. Edu-labelled flow cytometric analysis showed that the percentage of the Edu positive cells was increased in the treated cells. These results indicate that the enhanced proliferation involved hepatocytes rather than another cell type. Our investigations further revealed that these enhancements by FZHY are mediated through activation of canonical Wnt and ERK pathways and inhibition of Notch pathway. Thus, FZHY not only promoted hepatocyte differentiation and maturation, but also enhanced hepatocyte proliferation. These results demonstrate that FZHY appears to represent an excellent therapeutic agent for the treatment of liver fibrosis, and that FZHY treatment can enhance our efforts to generate mature hepatocytes with proliferative capacity for cell-based therapeutics and for pharmacological and toxicological studies.
[1]Shanghai Univ Tradit Chinese Med, Inst Liver Dis, Shuguang Hosp, Shanghai, Peoples R China.
[2]Univ Calif Davis, Med Ctr, Dept Internal Med, Sacramento, CA 95817 USA.
[3]Univ Calif Davis, Med Ctr, Inst Regenerat Cures, Sacramento, CA 95817 USA.
[4]Univ Calif Davis, Med Ctr, Dept Dermatol, Sacramento, CA 95817 USA.
[5]Chinese Acad Sci, Inst Biophys, Beijing 100080, Peoples R China.
[6]Shanghai Univ Tradit Chinese Med, E Inst Shanghai Municipal Educ Commiss, Shanghai, Peoples R China.
(8.0+极速模式)